L. L. Lazaro

发表

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

H. Rosing, E. Brain, J. Misset, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.